Table 1.
Baseline characteristics of women participating in the Bangkok Tenofovir Study, 2005–2012 (n=489).
| Characteristics | Tenofovir N=246 |
Placebo N=243 |
Total N=489 |
p-value |
|---|---|---|---|---|
| Age | ||||
| Median (IQR*) | 30 (26–35) | 30 (26–38) | 30 (26–36) | 0.18 |
| Education level | ||||
| Primary or less (<6 years) | 127 (51.6) | 133 (54.7) | 260 (53.2) | |
| Secondary or more | 119 (52.0) | 110 (48.0) | 229 (46.8) | 0.49 |
| Risk factors | ||||
| Incarceration | ||||
| In police holding cell past 12 weeks | 52 (21.1) | 49 (20.2) | 101 (20.7) | 0.79 |
| In prison in the past 12 weeks | 37 (15.0) | 30 (12.4) | 67 (13.7) | 0.39 |
| Drug use | ||||
| Currently in methadone program | 28 (11.4) | 34 (14.0) | 62 (12.7) | 0.39 |
| Injected drugs in past 12 weeks | 132 (53.7) | 134 (55.1) | 266 (54.4) | 0.74 |
| Heroin | 28 (11.4) | 32 (13.2) | 60 (12.3) | 0.55 |
| Methamphetamine | 87 (35.4) | 77 (31.7) | 164 (33.5) | 0.39 |
| Midazolam | 35 (14.2) | 33 (13.6) | 68 (13.9) | 0.84 |
| Other | 9 (3.7) | 15 (6.2) | 24 (4.9) | 0.20 |
| Injection frequency in past 12 weeks | ||||
| Every day | 16 (6.5) | 11 (4.5) | 27 (5.5) | 0.34 |
| Every week | 45 (18.3) | 49 (20.2) | 94 (19.2) | 0.60 |
| Less frequent than every week | 71 (28.9) | 74 (30.5) | 145 (29.7) | 0.70 |
| Shared needles in past 12 weeks | 38 (15.5) | 40 (16.5) | 78(16.0) | 0.76 |
| Sexual behaviors | ||||
| Number of opposite sex sexual partners in past 12 weeks | ||||
| 0 | 79 (32.1) | 67 (27.6) | 146 (29.9) | 0.27 |
| ≥1 | 167 (67.9) | 176 (72.4) | 343 (70.1) | 0.27 |
| Reported sexual intercourse with live-in partner in past 12 weeks | 134 (54.5) | 142 (58.4) | 276 (56.4) | 0.38 |
| Reported sexual intercourse with casual partner in past 12 weeks | 48 (19.5) | 58 (23.9) | 106 (21.7) | 0.24 |
Data are n/N (%) or n (%);
*
Interquartile range (IQR)